Simultaneous Kidney and Parathyroid Transplantation in the Management of Genetic Hypoparathyroidism in a Child.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
17
05
2021
revised:
29
08
2021
accepted:
19
09
2021
entrez:
23
3
2022
pubmed:
24
3
2022
medline:
24
3
2022
Statut:
epublish
Résumé
Genetically determined hypoparathyroidism can lead to life-threatening episodes of hypocalcemia and, more rarely, to end-stage kidney disease at a young age. Parathyroid allotransplantation is the only curative treatment, and in patients already receiving immunosuppression for kidney transplantation, there may be little additional risk involved. We report the first such case in a child. An 11-y-old girl, known to have hypoparathyroidism secondary to an activating pathogenic variant in the calcium-sensing receptor, developed end-stage kidney disease and was started on intermittent hemodialysis. Since the age of 2.5 y, she had been receiving treatment with exogenous synthetic parathyroid hormone (PTH). In June 2019, at the age of 11.8 y, she received a living-donor kidney and simultaneous parathyroid gland transplant from her father. The kidney was implanted into the right iliac fossa, followed by implantation of the parathyroid gland into the exposed rectus muscle. The kidney graft showed immediate function while the intrinsic serum PTH level remained low at 3 ng/L. Exogenous PTH infusion was reduced on day 6 posttransplantation to stimulate PTH production by the new gland, which resulted in improving intrinsic PTH concentrations of 28 ng/L by day 9. Twelve months after transplantation, PTH levels remain in normal range and the kidney graft function is stable with a serum creatinine of 110 μmol/L. Simultaneous living donation and transplantation of a kidney and a parathyroid gland into a child is safe and feasible and has the potential to cure primary hypoparathyroidism as well as kidney failure.
Sections du résumé
Background
UNASSIGNED
Genetically determined hypoparathyroidism can lead to life-threatening episodes of hypocalcemia and, more rarely, to end-stage kidney disease at a young age. Parathyroid allotransplantation is the only curative treatment, and in patients already receiving immunosuppression for kidney transplantation, there may be little additional risk involved. We report the first such case in a child.
Methods
UNASSIGNED
An 11-y-old girl, known to have hypoparathyroidism secondary to an activating pathogenic variant in the calcium-sensing receptor, developed end-stage kidney disease and was started on intermittent hemodialysis. Since the age of 2.5 y, she had been receiving treatment with exogenous synthetic parathyroid hormone (PTH). In June 2019, at the age of 11.8 y, she received a living-donor kidney and simultaneous parathyroid gland transplant from her father. The kidney was implanted into the right iliac fossa, followed by implantation of the parathyroid gland into the exposed rectus muscle.
Results
UNASSIGNED
The kidney graft showed immediate function while the intrinsic serum PTH level remained low at 3 ng/L. Exogenous PTH infusion was reduced on day 6 posttransplantation to stimulate PTH production by the new gland, which resulted in improving intrinsic PTH concentrations of 28 ng/L by day 9. Twelve months after transplantation, PTH levels remain in normal range and the kidney graft function is stable with a serum creatinine of 110 μmol/L.
Conclusions
UNASSIGNED
Simultaneous living donation and transplantation of a kidney and a parathyroid gland into a child is safe and feasible and has the potential to cure primary hypoparathyroidism as well as kidney failure.
Identifiants
pubmed: 35317006
doi: 10.1097/TXD.0000000000001284
pmc: PMC8929518
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1284Informations de copyright
Copyright © 2022 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Am J Transplant. 2010 Sep;10(9):2061-5
pubmed: 20883540
Tohoku J Exp Med. 1991 Sep;165(1):33-40
pubmed: 1798975
Exp Clin Transplant. 2016 Apr;14(2):238-41
pubmed: 25476143
Gland Surg. 2017 Oct;6(5):530-536
pubmed: 29142845
Transplantation. 2016 Jun;100(6):1318-21
pubmed: 26760567
Semin Surg Oncol. 1990;6(2):115-21
pubmed: 2180041
Nat Rev Dis Primers. 2017 Aug 31;3:17055
pubmed: 28857066
J Microencapsul. 1997 Sep-Oct;14(5):617-26
pubmed: 9292437
Transplant Proc. 1997 Feb-Mar;29(1-2):998-1000
pubmed: 9123623
Pediatr Nephrol. 2017 Jun;32(6):987-996
pubmed: 28188436
Transplant Proc. 2019 Nov;51(9):3186-3188
pubmed: 31371218
Thyroid. 2005 Nov;15(11):1299-302
pubmed: 16356096
Ann Pediatr Endocrinol Metab. 2018 Jun;23(2):107-111
pubmed: 29969884
Lancet. 1973 May 19;1(7812):1082-5
pubmed: 4122009
Surgery. 1992 Feb;111(2):234-6
pubmed: 1736395
Transplant Proc. 2009 Mar;41(2):599-600
pubmed: 19328935
Transplantation. 2007 Mar 27;83(6):734-40
pubmed: 17414706
Surgery. 1985 Dec;98(6):1072-6
pubmed: 4071384
Transplant Proc. 2009 Nov;41(9):3879-83
pubmed: 19917405
Experientia. 1979 Apr 15;35(4):559-60
pubmed: 437060
Transpl Int. 2014 Jun;27(6):e43-5
pubmed: 24438470
Acta Chir Scand. 1983;149(6):545-54
pubmed: 6650065
Arch Dis Child. 2016 Sep;101(9):e2
pubmed: 27540249
Harefuah. 2017 Mar;156(3):167-170
pubmed: 28551934
Exp Clin Transplant. 2016 Aug;14(4):431-5
pubmed: 26375142
Microsurgery. 2003;23(5):503-7
pubmed: 14558011
Surgery. 1975 Jul;78(1):34-44
pubmed: 1138398